Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on immunology-based therapies, will host one-on-one investor meetings at two upcoming conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15, 2021, and the Cantor Fitzgerald Virtual Global Healthcare Conference will take place from September 27-30, 2021. Ampio's lead drug, Ampion™, which aims to treat prevalent inflammatory conditions, has a patent portfolio extending through 2037 and could secure 12-year FDA market exclusivity upon approval.

ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will host one-on-one investor meetings at the following investor conferences:

H.C. Wainwright 23^rd Annual Global Investment Conference
Date:  September 13-15, 2021

Cantor Fitzgerald Virtual Global Healthcare Conference
Date:  September 27-30, 2021

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).

Forward Looking Statements

Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "could," "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's ability to access equity financing and fund research and development programs and operations through the fourth quarter of 2022, expectations with respect to Ampion, including its ability to treat prevalent inflammatory conditions for which there are limited treatment options (including COVID-19) and its ability to offer the benefits of steroids without the side effects, the significance of reported results in early clinical trials, the timing of patient enrollment for the Phase I Long-COVID trial and the Phase II COVID-19 trials, the timing and outcome of the Company's application for Emergency Use Authorization of Ampion in COVID-19 patients with inhalation and intravenous routes of drug delivery, the term of Ampion's patent protection and the timing and likelihood of Ampion's approval as a novel biologic under the BPCIA, including the availability of 12-year FDA market exclusivity in connection with such approval. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Ampio and are subject to significant risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, in Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact

Katie Kennedy
katie@gregoryfca.com 
610-731-1045

View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-301352299.html

SOURCE Ampio Pharmaceuticals, Inc.

FAQ

What is Ampio Pharmaceuticals' participation in investor conferences?

Ampio Pharmaceuticals will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021.

What is Ampion™ and its significance for Ampio Pharmaceuticals?

Ampion™ is Ampio Pharmaceuticals' lead drug aimed at treating prevalent inflammatory conditions, backed by a patent portfolio that extends through 2037 and offers potential 12-year FDA market exclusivity.

What are the future plans for Ampio Pharmaceuticals regarding Ampion™?

Ampio plans to apply for Emergency Use Authorization of Ampion™ for COVID-19 patients, focusing on both inhalation and intravenous delivery methods.

What financial outlook does Ampio Pharmaceuticals have for 2022?

Ampio anticipates funding its research and development programs through the fourth quarter of 2022, relying on equity financing.

What are the upcoming dates for investor conferences involving AMPE?

The upcoming investor conferences for Ampio Pharmaceuticals (AMPE) are on September 13-15, 2021, and September 27-30, 2021.